Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ARTELO BIOSCIENCES, INC. (ARTL)

Artelo Biosciences sets up $6.53 million at-the-market stock sale program; faces arbitration claim

Mixed Impact 3 of 5 financing Written later

Artelo Biosciences entered a sales agreement with H.C. Wainwright & Co. allowing it to sell up to $6,530,000 of common stock through an at-the-market program, paying the agent a 3.0% commission on gross sales. Separately, Craft Capital Management filed a FINRA arbitration claim against the company over a right of first refusal tied to a March 2026 private placement. The stock sales could dilute existing shareholders, and the outcome of the arbitration is not addressed in the filing.

Key points

  • Sales agreement dated May 26, 2026 allows sales of up to $6,530,000 of common stock, par value $0.001 per share
  • Sales agent receives a 3.0% commission on gross sales price; company has no obligation to sell any shares
  • Craft Capital seeks an $880,000 success fee, warrants valued at $880,000, monthly late fees and attorneys' fees over the March 30, 2026 private placement, which raised gross proceeds of about $11 million

The filing

CompanyARTELO BIOSCIENCES, INC. (ARTL)
Form8-K, current report
Filed with the SECMay 27, 2026, 4:39 PM ET
Accession number0001640334-26-000973

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.